B. LifeLiver

LifeLiver is a South Korean biotechnology company specializing in the development of bio-artificial liver systems and regenerative cell therapies for severe liver diseases. The company's flagship technology, the LifeLiver system, is an extracorporeal bio-artificial liver (BAL) that utilizes porcine hepatocytes to perform essential metabolic and detoxification functions for patients with acute liver failure. This system serves as a critical bridge to liver transplantation or as a support mechanism to allow for natural liver regeneration. Following its acquisition by the HLB Group, LifeLiver has integrated its expertise into a broader life sciences framework, focusing on advancing its clinical pipeline and expanding its cell therapy applications. The company remains a pioneer in the field of artificial organ support within the Asian biopharmaceutical market.